We are live on ! Find out more
NVS icon

Novartis

1,219 hedge funds and large institutions have $15.1B invested in Novartis in 2023 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 377 increasing their positions, 445 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 60

23% more funds holding in top 10

Funds holding in top 10: 13 → 16 (+3)

2% more funds holding

Funds holding: 1,198 → 1,219 (+21)

3% more capital inflows, than outflows

Capital inflows: $636M | Capital outflows: $619M

0.11% more ownership

Funds ownership: 7.06% → 7.17% (+0.11%)

6% less call options, than puts

Call options by funds: $253M | Put options by funds: $270M

15% less repeat investments, than reductions

Existing positions increased: 377 | Existing positions reduced: 445

Holders
1,219
Holders Change
+21
Holders Change %
+1.75%
% of All Funds
19.3%
Holding in Top 10
16
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+23.08%
% of All Funds
0.25%
New
88
Increased
377
Reduced
445
Closed
60
Calls
$253​M
Puts
$270​M
Net Calls
-⁠$16.3​M
Net Calls Change
-⁠$401​M

NVS Hedge Fund Activity: Q3 2023 in Review

1,219 of the 6,315 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2023, worth a combined $15.1B — up 1% from $14.9B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new NVS positions and 60 closed out — a net gain of 28 holders — while 377 added to existing stakes and 445 trimmed.

The largest buyer was Grantham, Mayo, Van Otterloo & Co (GMO), adding an estimated $116M. The largest seller was Point72 Asset Management, cutting an estimated $73.6M.

  • 1,219 institutional investors held Novartis (NVS) as of Q3 2023, up from 1,198 in Q2 2023.
  • Funds reported $15.1B of Novartis stock for Q3 2023, up 1% quarter-over-quarter.
  • 88 funds opened new Novartis positions in Q3 2023 and 60 closed out, a net change of +28 holders.
  • The largest Novartis buyer in Q3 2023 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $116M added.
  • The largest Novartis seller in Q3 2023 was Point72 Asset Management, an estimated $73.6M sold.

Based on aggregated 13F filings for Q3 2023.